<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6703">
  <stage>Registered</stage>
  <submitdate>14/08/2017</submitdate>
  <approvaldate>14/08/2017</approvaldate>
  <nctid>NCT03251248</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetic/Pharmacodynamic Equivalence of MSB11455 in Healthy Subjects</studytitle>
    <scientifictitle>A Randomized, Double-blind, Crossover Study to Compare the Pharmacokinetic and Pharmacodynamic Bioequivalence of a Single Injection of MSB11455 and Neulasta in Healthy Adult Subjects</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EMR200621-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Healthy</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - MSB11455
Treatment: drugs - Neulasta

Experimental: First MSB11455 Then Neulasta - 

Experimental: First Neulasta Then MSB11455 - 


Treatment: drugs: MSB11455
Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.

Treatment: drugs: Neulasta
Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Area Under the Concentration-Time Curve From Time Zero (Pre-dose) to Time of Last Quantifiable Concentration AUC(0-last) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area Under the Concentration-Time Curve From Time Zero (Pre-dose) Extrapolated to Infinity AUC(0-inf) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum Observed Plasma Concentration (Cmax) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Maximum Observed Effect (Emax) for Absolute Neutrophil Count (ANC) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Area Under the Effect-Time Curve From Time Zero (Pre-dose) to Last Measured Time (AUE0-t) for (ANC) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Maximum Observed Plasma Concentration (tmax) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Last Observed Plasma Concentration (tlast) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Terminal rate constant (?z) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Terminal Half-life (t1/2) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apparent Total Plasma Clearance (CL/F) of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Maximum Observed Effect (tEmax) for ANC of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under Effect Curve from zero to 360 hours (AUEC0-360) for ANC of MSB11455 and Neulasta</outcome>
      <timepoint>Pre-dose up to 15 days post-dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Safety Profile as Assessed by Clinical Adverse events (AEs), Laboratory Variables, Vital Signs, Incidence of Antidrug Antibodies (ADAs), Neutralizing Antibodies(NABs) - Safety assessment will be based on number of subjects with AEs, abnormal laboratory variables, abnormal vital signs, incidence of ADAs and NABs</outcome>
      <timepoint>Day 1 up to a maximum of 15 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects who provide signed and dated written informed consent

          -  Other protocol defined inclusion criteria could apply</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Subjects who have no known hypersensitivity to any component of Neulasta or MSB11455,
             and laboratory test results within predefined ranges

          -  Other protocol defined exclusion criteria could apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Other</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>22/08/2017</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>344</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>31/10/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Nucleus Network - Melbourne</hospital>
    <postcode>3004 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Merck KGaA</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to compare the pharmacokinetics (PK) and pharmacodynamics (PD) of
      MSB11455 and Neulasta in healthy adult subjects.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03251248</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Responsible</name>
      <address>Merck KGaA</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Merck KGaA Communication Center</name>
      <address />
      <phone>+49 6151 72 5200</phone>
      <fax />
      <email>service@merckgroup.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>